Hologic (HOLX) Reports In-Line Q2 EPS; Lowers Rev Guidance, Maintains EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hologic (HOLX) PT Lowered to $40 at RBC Capital
May 3, 2018 8:47 AM EDTRBC Capital lowered its price target on Hologic (NASDAQ: HOLX) to $40.00 (from $44.00) while maintaining a Sector Perform rating.
... MoreHologic (HOLX) PT Lowered to $40.50 at Evercore ISI
May 3, 2018 7:37 AM EDTEvercore ISI lowered its price target on Hologic (NASDAQ: HOLX) to $40.50 (from $42.50) while maintaining a Outperform rating.
... MoreHologic (HOLX) PT Lowered to $43 at Needham & Company; 'Ugly Write-Down for Aesthetics Business'
May 3, 2018 6:43 AM EDTNeedham & Company lowered its price target on Hologic (NASDAQ: HOLX) to $43.00 (from $50.00) while maintaining a Buy rating.
Analyst Mike Matson commented, " HOLX's F2Q18 revenue beat and EPS met consensus. But management lowered its FY18 revenue guidance due to Cynosure and... More
Canaccord Genuity Downgrades Hologic (HOLX) to Hold
May 3, 2018 4:40 AM EDTCanaccord Genuity downgraded Hologic (NASDAQ: HOLX) from Buy to Hold with a price target of $39.00 (from $48.00).
Analyst Mark Massaro comments "We think HOLX may "figure it out," but we now believe the turnaround of Cynosure will take longer than we expected,... More
